1:"$Sreact.fragment"
2:I[9881,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","187","static/chunks/187-9968f21ecf164052.js","177","static/chunks/app/layout-fa7cba4b34f22bd9.js"],"default"]
3:I[7555,[],""]
4:I[1295,[],""]
5:I[6874,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],""]
e:I[8393,[],""]
:HL["/_next/static/media/e4af272ccee01ff0-s.p.woff2","font",{"crossOrigin":"","type":"font/woff2"}]
:HL["/_next/static/css/5884bd3aaf456fca.css","style"]
:HL["/_next/static/css/931b179cff3131dc.css","style"]
0:{"P":null,"b":"Xd76CUF9_ROIgMmQRWBvv","p":"","c":["","drugs","mounjaro-d2d7da5",""],"i":false,"f":[[["",{"children":["drugs",{"children":[["slug","mounjaro-d2d7da5","d"],{"children":["__PAGE__",{}]}]}]},"$undefined","$undefined",true],["",["$","$1","c",{"children":[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/5884bd3aaf456fca.css","precedence":"next","crossOrigin":"$undefined","nonce":"$undefined"}],["$","link","1",{"rel":"stylesheet","href":"/_next/static/css/931b179cff3131dc.css","precedence":"next","crossOrigin":"$undefined","nonce":"$undefined"}]],["$","html",null,{"lang":"en","data-scroll-behavior":"smooth","children":[["$","head",null,{"children":[["$","link",null,{"rel":"dns-prefetch","href":"//fonts.googleapis.com"}],["$","link",null,{"rel":"preconnect","href":"https://fonts.googleapis.com","crossOrigin":"anonymous"}],["$","link",null,{"rel":"preload","href":"/og-image.png","as":"image"}],["$","link",null,{"rel":"icon","type":"image/x-icon","href":"/favicon.ico"}],["$","link",null,{"rel":"icon","type":"image/png","sizes":"32x32","href":"/og-image.png"}],["$","link",null,{"rel":"icon","type":"image/png","sizes":"16x16","href":"/og-image.png"}],["$","link",null,{"rel":"apple-touch-icon","href":"/og-image.png"}],["$","meta",null,{"name":"theme-color","content":"#3B82F6"}],["$","link",null,{"rel":"manifest","href":"/manifest.json"}]]}],["$","body",null,{"className":"__className_e8ce0c","children":[["$","div",null,{"className":"flex min-h-screen flex-col","children":[["$","$L2",null,{}],["$","main",null,{"className":"flex-1","role":"main","children":["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":[["$","div",null,{"className":"container mx-auto px-4 py-16","children":["$","div",null,{"className":"max-w-2xl mx-auto","children":["$","div",null,{"ref":"$undefined","className":"rounded-lg border bg-card text-card-foreground shadow-sm","children":[["$","div",null,{"ref":"$undefined","className":"flex flex-col space-y-1.5 p-6 text-center","children":[["$","div",null,{"ref":"$undefined","className":"tracking-tight text-6xl font-bold text-gray-300","children":"404"}],["$","div",null,{"ref":"$undefined","className":"text-muted-foreground text-xl mt-4","children":"Page Not Found"}]]}],["$","div",null,{"ref":"$undefined","className":"p-6 pt-0 text-center space-y-6","children":[["$","p",null,{"className":"text-gray-600","children":"The page you're looking for doesn't exist or has been moved."}],["$","div",null,{"className":"flex flex-col sm:flex-row gap-4 justify-center","children":[["$","$L5",null,{"href":"/","children":["$","button",null,{"className":"inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg]:size-4 [&_svg]:shrink-0 bg-primary text-primary-foreground hover:bg-primary/90 h-10 px-4 py-2 w-full sm:w-auto","ref":"$undefined","children":[["$","svg",null,{"ref":"$undefined","xmlns":"http://www.w3.org/2000/svg","width":24,"height":24,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-house mr-2 h-4 w-4","children":[["$","path","5wwlr5",{"d":"M15 21v-8a1 1 0 0 0-1-1h-4a1 1 0 0 0-1 1v8"}],["$","path","1d0kgt",{"d":"M3 10a2 2 0 0 1 .709-1.528l7-5.999a2 2 0 0 1 2.582 0l7 5.999A2 2 0 0 1 21 10v9a2 2 0 0 1-2 2H5a2 2 0 0 1-2-2z"}],"$undefined"]}],"Go Home"]}]}],["$","$L5",null,{"href":"/search","children":["$","button",null,{"className":"inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg]:size-4 [&_svg]:shrink-0 border border-input bg-background hover:bg-accent hover:text-accent-foreground h-10 px-4 py-2 w-full sm:w-auto","ref":"$undefined","children":[["$","svg",null,{"ref":"$undefined","xmlns":"http://www.w3.org/2000/svg","width":24,"height":24,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-search mr-2 h-4 w-4","children":["$L6","$L7","$undefined"]}],"Search Drugs"]}]}]]}]]}]]}]}]}],[]],"forbidden":"$undefined","unauthorized":"$undefined"}]}],"$L8"]}],"$L9"]}]]}]]}],{"children":["drugs","$La",{"children":[["slug","mounjaro-d2d7da5","d"],"$Lb",{"children":["__PAGE__","$Lc",{},null,false]},null,false]},null,false]},null,false],"$Ld",false]],"m":"$undefined","G":["$e",[]],"s":false,"S":true}
f:I[6471,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","187","static/chunks/187-9968f21ecf164052.js","177","static/chunks/app/layout-fa7cba4b34f22bd9.js"],"Toaster"]
11:I[9665,[],"OutletBoundary"]
13:I[4911,[],"AsyncMetadataOutlet"]
15:I[9665,[],"ViewportBoundary"]
17:I[9665,[],"MetadataBoundary"]
18:"$Sreact.suspense"
6:["$","circle","4ej97u",{"cx":"11","cy":"11","r":"8"}]
7:["$","path","1qie3q",{"d":"m21 21-4.3-4.3"}]
8:["$","footer",null,{"className":"bg-medical-gray-800 text-medical-gray-300 mt-16","children":["$","div",null,{"className":"max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-12","children":[["$","div",null,{"className":"grid grid-cols-1 md:grid-cols-4 gap-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"text-lg font-semibold text-white mb-4","children":"drugfacts.wiki"}],["$","p",null,{"className":"text-sm","children":"Comprehensive FDA drug information for healthcare professionals"}]]}],[["$","div","Resources",{"children":[["$","h4",null,{"className":"font-semibold text-white mb-3","children":"Resources"}],["$","ul",null,{"className":"space-y-2 text-sm","children":[["$","li","Drug Search",{"children":["$","$L5",null,{"href":"/search","className":"hover:text-white transition-colors","children":"Drug Search"}]}],["$","li","Therapeutic Classes",{"children":["$","$L5",null,{"href":"/therapeutic-classes","className":"hover:text-white transition-colors","children":"Therapeutic Classes"}]}],["$","li","Drug Interactions",{"children":["$","$L5",null,{"href":"/interactions","className":"hover:text-white transition-colors","children":"Drug Interactions"}]}]]}]]}],["$","div","Support",{"children":[["$","h4",null,{"className":"font-semibold text-white mb-3","children":"Support"}],["$","ul",null,{"className":"space-y-2 text-sm","children":[["$","li","Contact Us",{"children":["$","$L5",null,{"href":"/contact","className":"hover:text-white transition-colors","children":"Contact Us"}]}],["$","li","FAQ",{"children":["$","$L5",null,{"href":"/faq","className":"hover:text-white transition-colors","children":"FAQ"}]}],["$","li","Terms of Service",{"children":["$","$L5",null,{"href":"/terms","className":"hover:text-white transition-colors","children":"Terms of Service"}]}]]}]]}],["$","div","Legal",{"children":[["$","h4",null,{"className":"font-semibold text-white mb-3","children":"Legal"}],["$","ul",null,{"className":"space-y-2 text-sm","children":[["$","li","Privacy Policy",{"children":["$","$L5",null,{"href":"/privacy","className":"hover:text-white transition-colors","children":"Privacy Policy"}]}],["$","li","Disclaimer",{"children":["$","$L5",null,{"href":"/disclaimer","className":"hover:text-white transition-colors","children":"Disclaimer"}]}],["$","li","Accessibility",{"children":["$","$L5",null,{"href":"/accessibility","className":"hover:text-white transition-colors","children":"Accessibility"}]}]]}]]}]]]}],["$","div",null,{"className":"border-t border-medical-gray-700 mt-8 pt-8 text-center text-sm","children":["$","p",null,{"children":"Â© 2025 drugfacts.wiki. All rights reserved. This information is for healthcare professionals only."}]}]]}]}]
9:["$","$Lf",null,{}]
a:["$","$1","c",{"children":[null,["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}]
b:["$","$1","c",{"children":[null,["$","$L3",null,{"parallelRouterKey":"children","error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L4",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","forbidden":"$undefined","unauthorized":"$undefined"}]]}]
c:["$","$1","c",{"children":["$L10",null,["$","$L11",null,{"children":["$L12",["$","$L13",null,{"promise":"$@14"}]]}]]}]
d:["$","$1","h",{"children":[null,[["$","$L15",null,{"children":"$L16"}],["$","meta",null,{"name":"next-size-adjust","content":""}]],["$","$L17",null,{"children":["$","div",null,{"hidden":true,"children":["$","$18",null,{"fallback":null,"children":"$L19"}]}]}]]}]
16:[["$","meta","0",{"charSet":"utf-8"}],["$","meta","1",{"name":"viewport","content":"width=device-width, initial-scale=1"}]]
12:null
14:{"metadata":[["$","title","0",{"children":"Mounjaro (tirzepatide) | drugfacts.wiki"}],["$","meta","1",{"name":"description","content":"Complete prescribing information for Mounjaro (tirzepatide). Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dosing, s..."}],["$","meta","2",{"name":"author","content":"drugfacts.wiki"}],["$","meta","3",{"name":"keywords","content":"mounjaro, tirzepatide, glp-1/gip receptor agonist, prescribing information, drug facts, medical information, diabetes"}],["$","meta","4",{"name":"robots","content":"index, follow"}],["$","meta","5",{"name":"googlebot","content":"index, follow, max-video-preview:-1, max-image-preview:large, max-snippet:-1"}],["$","meta","6",{"property":"og:title","content":"Mounjaro - Professional Drug Information"}],["$","meta","7",{"property":"og:description","content":"Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Complete prescribing information including dosing, contraindications, and safety data."}],["$","meta","8",{"property":"og:site_name","content":"drugfacts.wiki"}],["$","meta","9",{"property":"og:type","content":"article"}],["$","meta","10",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","11",{"name":"twitter:title","content":"Mounjaro - Professional Drug Information"}],["$","meta","12",{"name":"twitter:description","content":"Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Complete prescribing information including dosing, contraindications, and safety data."}]],"error":null,"digest":"$undefined"}
19:"$14:metadata"
1a:I[2581,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"default"]
1b:I[64,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"Root"]
10:["$","div",null,{"className":"container mx-auto px-2 sm:px-4 py-4 sm:py-8","children":["$","div",null,{"className":"grid grid-cols-1 lg:grid-cols-4 gap-4 lg:gap-8","children":[["$","div",null,{"className":"lg:col-span-3","children":[["$","$L1a",null,{"drug":{"drugName":"Mounjaro","genericName":"tirzepatide","slug":"mounjaro-d2d7da5","setId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","activeIngredient":"tirzepatide","therapeuticClass":"GLP-1/GIP Receptor Agonist","manufacturer":"Eli Lilly and Company","boxedWarning":"<p><strong>WARNING: RISK OF THYROID C-CELL TUMORS</strong></p><p>In rodents, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.</p>","indicationsAndUsage":"<p>MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p>","dosageAndAdministration":"<p>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</p>","contraindications":"<p>MOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.</p>","warnings":"<p><strong>Pancreatitis:</strong> Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.</p>","adverseReactions":"<p>The most common adverse reactions reported in â¥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.</p>","drugInteractions":"<p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.</p>","clinicalPharmacology":"<p>Tirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life.</p>","clinicalStudies":"<p>The efficacy of MOUNJARO was evaluated in five multicenter, randomized, controlled trials in adult patients with type 2 diabetes.</p>","howSupplied":"<p>MOUNJARO is supplied as a single-dose pen containing a 0.5 mL solution in the following dosage strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.</p>","patientCounseling":"<p>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</p>","description":"<p>MOUNJARO contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide.</p>","overdosage":"<p>In the event of overdosage, contact Poison Control for latest recommendations. Based on the pharmacological actions of tirzepatide, an overdose may result in gastrointestinal adverse reactions and hypoglycemia.</p>","nonClinicalToxicology":"<p>In a 2-year carcinogenicity study in rats, tirzepatide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell adenomas and carcinomas.</p>","principalDisplayPanel":"<p>NDC 0002-1434-80<br/>MOUNJAROâ¢<br/>(tirzepatide) injection<br/>2.5 mg/0.5 mL<br/>For subcutaneous use only<br/>Single-Dose Pen<br/>Rx only</p>"}}],["$","$L1b",null,{"defaultValue":"professional","className":"mt-4 sm:mt-6","children":["$L1c","$L1d","$L1e","$L1f"]}]]}],"$L20"]}]}]
21:I[64,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"List"]
22:I[64,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"Trigger"]
23:I[64,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"Content"]
24:I[9717,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"default"]
2c:I[3488,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"default"]
2d:I[3474,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"default"]
2e:I[4473,["874","static/chunks/874-437a265a67d6cfee.js","455","static/chunks/455-28b7fbb360ee31f4.js","496","static/chunks/496-4ec65330a7ffa1d1.js","42","static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js"],"default"]
1c:["$","$L21",null,{"ref":"$undefined","className":"items-center justify-center text-muted-foreground flex w-full h-auto p-1 bg-gray-100 border border-gray-200 rounded-lg","children":[["$","$L22",null,{"ref":"$undefined","className":"inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative","value":"professional","children":[["$","span",null,{"className":"block sm:hidden","children":"Professional"}],["$","span",null,{"className":"hidden sm:block","children":"Professional Info"}]]}],["$","$L22",null,{"ref":"$undefined","className":"inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative","value":"patient","children":[["$","span",null,{"className":"block sm:hidden","children":"Patient"}],["$","span",null,{"className":"hidden sm:block","children":"Patient-Friendly"}]]}],["$","$L22",null,{"ref":"$undefined","className":"inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative","value":"faq","children":[["$","span",null,{"className":"block sm:hidden","children":"FAQ"}],["$","span",null,{"className":"hidden sm:block","children":"FAQ & Related"}]]}]]}]
1d:["$","$L23",null,{"ref":"$undefined","className":"ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6","value":"professional","children":[["$","div",null,{"className":"bg-blue-50 border border-blue-200 rounded-lg p-1","children":["$","$L24",null,{"id":"highlights","title":"HIGHLIGHTS","defaultExpanded":true,"children":["$","div",null,{"className":"prose max-w-none","children":[["$","h4",null,{"className":"text-sm font-medium text-blue-900 mb-2","children":"Dosage and Administration Highlights"}],["$","div",null,{"dangerouslySetInnerHTML":{"__html":"<p>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</p>"}}]]}]}]}],["$","div",null,{"className":"border-2 border-red-500 bg-red-50 rounded-lg p-1","children":["$","$L24",null,{"id":"boxed-warning","title":"BOXED WARNING","defaultExpanded":true,"children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p><strong>WARNING: RISK OF THYROID C-CELL TUMORS</strong></p><p>In rodents, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.</p>"}}]}]}],"$undefined",["$","$L24",null,{"id":"indications","title":"INDICATIONS AND USAGE","defaultExpanded":true,"children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p>"}}]}],["$","$L24",null,{"id":"dosage","title":"DOSAGE AND ADMINISTRATION","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</p>"}}]}],"$undefined",["$","$L24",null,{"id":"contraindications","title":"CONTRAINDICATIONS","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>MOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.</p>"}}]}],["$","$L24",null,{"id":"warnings","title":"WARNINGS AND PRECAUTIONS","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p><strong>Pancreatitis:</strong> Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.</p>"}}]}],["$","$L24",null,{"id":"adverse-reactions","title":"ADVERSE REACTIONS","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>The most common adverse reactions reported in â¥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.</p>"}}]}],["$","$L24",null,{"id":"drug-interactions","title":"DRUG INTERACTIONS","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.</p>"}}]}],"$undefined",["$","$L24",null,{"id":"clinical-pharmacology","title":"CLINICAL PHARMACOLOGY","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>Tirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life.</p>"}}]}],"$undefined",["$","$L24",null,{"id":"nonclinical-toxicology","title":"NONCLINICAL TOXICOLOGY","children":"$L25"}],"$L26","$L27","$L28","$undefined","$L29","$L2a","$L2b"]}]
1e:["$","$L23",null,{"ref":"$undefined","className":"ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6","value":"patient","children":["$","$L2c",null,{"content":{"patientFriendlyName":"Mounjaro (tirzepatide)","whatItTreats":"Used to diet and exercise to improve glycemic control in adults who have type 2 diabetes.","howItWorks":"Tirzepatide is a modified peptide that diacid moiety that helps the medication last longer in your body.","commonSideEffects":["Nausea","Diarrhea","Vomiting","Constipation","Abdominal pain","Decreased appetite"],"importantSafetyInfo":"Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.","whenToCall":["Severe stomach pain that does not go away","Any severe or unusual side effects","Questions about your treatment"]}}]}]
1f:["$","$L23",null,{"ref":"$undefined","className":"ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6","value":"faq","children":[["$","$L2d",null,{"faqs":[{"question":"How should Mounjaro be taken?","answer":"The usual starting dose of MOUNJARO is 2.5 mg given as an injection under the skin once a week. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.","category":"dosing"},{"question":"Who should not take Mounjaro?","answer":"MOUNJARO should not be used by people with a personal or family history of certain types of thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.","category":"safety"},{"question":"What are the most common side effects of Mounjaro?","answer":"The most common adverse reactions experienced by 5% or more of people taking MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.","category":"side-effects"},{"question":"How should Mounjaro be stored?","answer":"Follow storage instructions on the package. Keep out of reach of children.","category":"storage"},{"question":"What conditions does Mounjaro treat?","answer":"Used to diet and exercise to improve glycemic control in adults who have type 2 diabetes.","category":"usage"}],"drugName":"Mounjaro"}],["$","$L2e",null,{"content":{"similarDrugs":[],"relatedConditions":["Diabetes"],"alternativeTreatments":["Diet and exercise","Metformin","Insulin therapy","SGLT-2 inhibitors"]}}]]}]
20:["$","div",null,{"className":"lg:col-span-1","children":["$","div",null,{"ref":"$undefined","className":"rounded-lg border bg-card text-card-foreground shadow-sm p-4 sm:p-6 sticky top-4 sm:top-8","children":[["$","h3",null,{"className":"font-semibold mb-4","children":"Drug Information"}],["$","dl",null,{"className":"space-y-3 text-sm","children":[["$","dt",null,{"className":"text-gray-600","children":"Drug Name"}],["$","dd",null,{"className":"font-medium","children":"Mounjaro"}],[["$","dt",null,{"className":"text-gray-600 mt-3","children":"Generic Name"}],["$","dd",null,{"className":"font-medium","children":"tirzepatide"}]],["$","dt",null,{"className":"text-gray-600 mt-3","children":"Set ID"}],["$","dd",null,{"className":"font-medium font-mono text-xs","children":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0"}],[["$","dt",null,{"className":"text-gray-600 mt-3","children":"Labeler"}],["$","dd",null,{"className":"font-medium","children":"Eli Lilly and Company"}]],"$undefined","$undefined",[["$","dt",null,{"className":"text-gray-600 mt-3","children":"Therapeutic Class"}],["$","dd",null,{"className":"font-medium","children":"GLP-1/GIP Receptor Agonist"}]],[["$","dt",null,{"className":"text-gray-600 mt-3","children":"Active Ingredient"}],["$","dd",null,{"className":"font-medium","children":"tirzepatide"}]],[["$","dt",null,{"className":"text-gray-600 mt-3","children":"Manufacturer"}],["$","dd",null,{"className":"font-medium","children":"Eli Lilly and Company"}]],"$undefined",["$","dt",null,{"className":"text-gray-600 mt-3","children":"Slug"}],["$","dd",null,{"className":"font-medium text-xs text-gray-500","children":"mounjaro-d2d7da5"}]]}],false]}]}]
25:["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>In a 2-year carcinogenicity study in rats, tirzepatide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell adenomas and carcinomas.</p>"}}]
26:["$","$L24",null,{"id":"clinical-studies","title":"CLINICAL STUDIES","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>The efficacy of MOUNJARO was evaluated in five multicenter, randomized, controlled trials in adult patients with type 2 diabetes.</p>"}}]}]
27:["$","$L24",null,{"id":"description","title":"DESCRIPTION","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>MOUNJARO contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide.</p>"}}]}]
28:["$","$L24",null,{"id":"how-supplied","title":"HOW SUPPLIED/STORAGE AND HANDLING","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>MOUNJARO is supplied as a single-dose pen containing a 0.5 mL solution in the following dosage strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.</p>"}}]}]
29:["$","$L24",null,{"id":"patient-counseling","title":"PATIENT COUNSELING INFORMATION","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</p>"}}]}]
2a:["$","$L24",null,{"id":"overdosage","title":"OVERDOSAGE","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>In the event of overdosage, contact Poison Control for latest recommendations. Based on the pharmacological actions of tirzepatide, an overdose may result in gastrointestinal adverse reactions and hypoglycemia.</p>"}}]}]
2b:["$","$L24",null,{"id":"principal-display-panel","title":"PRINCIPAL DISPLAY PANEL","children":["$","div",null,{"className":"prose max-w-none","dangerouslySetInnerHTML":{"__html":"<p>NDC 0002-1434-80<br/>MOUNJAROâ¢<br/>(tirzepatide) injection<br/>2.5 mg/0.5 mL<br/>For subcutaneous use only<br/>Single-Dose Pen<br/>Rx only</p>"}}]}]
